《新股消息》據報微醫重啟來港上市準備工作 最快明年上半年掛牌
外電報道,騰訊(00700.HK)持股的網上醫療平台微醫近日重啟來港上市初步準備工作,考慮最快明年上半年在港進行首次公開招股,但上市計劃最終能否落實,將要視乎監管機構的批准,預期微醫會在未來數月向港交所(00388.HK)徵求上市前意見。
微醫曾於去年4月曾向聯交所申請上市,當時傳出將集資最多30億美元,但由於內地當局加強規管企業對用戶數據等敏感資料的處理,微醫的香港上市申請已於同年10月失效。隨後曾有市場消息指,微醫考慮改以特殊目的收購公司(SPAC)方式上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.